Business
Manzo Pharmaceuticals starts laboratory testing of its lactose intolerance probiotic treatment
Manzo Pharmaceuticals starts laboratory testing of its lactose intolerance probiotic treatment.
About this update from Manzo Pharmaceuticals, Inc.
[{"type":"text","content":"\n\n\n\nManzo Pharmaceuticals starts laboratory testing of its lactose intolerance probiotic treatment\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nManzo Pharmaceuticals starts laboratory testing of its lactose intolerance probiotic treatment\nPR Newswire\nMILFORD, Pa., June 16, 2014\n\n\n\nMILFORD, Pa., June 16, 2014 /PRNewswire/ -- Fortune Oil & Gas, Inc. (OTCPink: FOGC), today announced that the company's wholly owned subsidiary, Manzo Pharmaceuticals has begun a series of laboratory testing for its patented probiotic formula, Lacto-Freedom™. Lacto-Freedom™ is designed to stop the symptoms of lactose intolerance for up to several months after taking it for just a short time. The company started a six month long study with different dosages of the probiotic to find the optimum amount needed to achieve the desired effect.  The safety of the product will also be confirmed over the course of this study and will prepare the product for human clinical trials. A stability test may also be performed to determine the best way to store the product and which dosage form is best (liquid, capsule, freeze dried powder, or pre-mixed in food) this study will bring Manzo Pharmaceuticals one-step closer to making this unique treatment available to the people who need it.\n\nThe Lacto-Freedom™ testing started on June 9th, and is being implemented by Celprogen®, Inc., a California based research facility specializing in drug studies and clinical trials such as this. Celprogen® has been conducting in-vitro and in-vivo biomedical research for over ten years. As a result, they are the perfect partners to implement these studies.\n\nThe company's CEO, Kenneth Manzo, has been working on a Lacto-Freedom™ Probiotic for over 10 years, and has high hopes for what he believes will completely change the lives of people who suffer with this condition. Lactose intolerance is the inability to digest lactose, a sugar found in milk and milk products. Currently, patients with lactose intolerance are limited to avoiding lactose-containing foods or taking ...